На этой странице перечислены больницы направления «Неврология» (включая Brain Tumor Surgery) в Дели (NCR), Индия, включая Apollo Hospitals, Medanta - The Medicity, Artemis Hospital, Fortis Memorial Research Institute и другие.
Спросите нас о «Brain Tumor Surgery» в Дели (NCR), Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 35 аккредитованных больниц (Неврология) в Дели (NCR), Индия
Рекомендуем🇮🇳 Apollo Hospitals
Больница занимает 1-е место в этом списке по указанному рейтингу (4.9/5, 1240 отзывов).
🇮🇳 Medanta - The Medicity
Больница занимает 2-е место в этом списке по указанному рейтингу (4.9/5, 2150 отзывов).
🇮🇳 Artemis Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.9/5, 64 отзывов).
🇮🇳 Fortis Memorial Research Institute
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 1100 отзывов).
🇮🇳 Max Super Specialty Hospital
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 1300 отзывов).
🇮🇳 All India Institute of Medical Sciences (AIIMS)
Больница занимает 6-е место в этом списке по указанному рейтингу (4.7/5, 3500 отзывов).
🇮🇳 CK Birla Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.7/5, 162 отзывов).
🇮🇳 Centre for Sight
Больница занимает 8-е место в этом списке по указанному рейтингу (4.7/5, 181 отзывов).
🇮🇳 Max Super Specialty Hospital, Gurgaon
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 95 отзывов).
🇮🇳 Max Super Speciality Hospital, Patparganj
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 97 отзывов).
🇮🇳 Primus Super Speciality Hospital
Больница занимает 11-е место в этом списке по указанному рейтингу (4.6/5, 142 отзывов).
🇮🇳 PSRI Multispeciality Hospital
Больница занимает 12-е место в этом списке по указанному рейтингу (4.6/5, 318 отзывов).
🇮🇳 Fortis Hospital, Shalimar Bagh
Больница занимает 13-е место в этом списке по указанному рейтингу (4.5/5, 68 отзывов).
🇮🇳 Sarvodaya Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.5/5, 74 отзывов).
🇮🇳 Indian Spinal Injuries Center
Больница занимает 15-е место в этом списке по указанному рейтингу (4.5/5, 76 отзывов).
🇮🇳 Max Super Speciality Hospital, Shalimar Bagh
Больница занимает 16-е место в этом списке по указанному рейтингу (4.5/5, 82 отзывов).
🇮🇳 Fortis Hospital, Noida
Больница занимает 17-е место в этом списке по указанному рейтингу (4.5/5, 88 отзывов).
🇮🇳 Venkateshwar Hospital
Больница занимает 18-е место в этом списке по указанному рейтингу (4.5/5, 69 отзывов).
🇮🇳 CK Birla Hospital
Больница занимает 19-е место в этом списке по указанному рейтингу (4.5/5, 72 отзывов).
🇮🇳 Fortis Flt. Lt. Rajan Dhall Hospital
Больница занимает 20-е место в этом списке по указанному рейтингу (4.5/5, 75 отзывов).
🇮🇳 Asian Institute of Medical Sciences
Больница занимает 21-е место в этом списке по указанному рейтингу (4.5/5, 119 отзывов).
🇮🇳 Manipal Hospitals Dwarka
Больница занимает 22-е место в этом списке по указанному рейтингу (4.4/5, 54 отзывов).
🇮🇳 Sir Ganga Ram Hospital
Больница занимает 23-е место в этом списке по указанному рейтингу (4.4/5, 24 отзывов).
🇮🇳 Fortis Escorts Hospital
Больница занимает 24-е место в этом списке по указанному рейтингу (4.4/5, 31 отзывов).
🇮🇳 Marengo Asia Hospitals
Больница занимает 25-е место в этом списке по указанному рейтингу (4.4/5, 54 отзывов).
🇮🇳 Yatharth Super Specialty Hospital
Больница занимает 26-е место в этом списке по указанному рейтингу (4.4/5, 61 отзывов).
🇮🇳 Paras Hospitals
Больница занимает 27-е место в этом списке по указанному рейтингу (4.4/5, 59 отзывов).
🇮🇳 Fortis Hospital Manesar
Больница занимает 28-е место в этом списке по указанному рейтингу (4.4/5, 74 отзывов).
🇮🇳 Marengo Asia Hospitals Gurgaon
Больница занимает 29-е место в этом списке по указанному рейтингу (4.4/5, 103 отзывов).
🇮🇳 Metro Hospital Noida
Больница занимает 30-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Sharda Hospital
Больница занимает 31-е место в этом списке по указанному рейтингу (4.4/5, 130 отзывов).
🇮🇳 Fortis Hospital, Greater Noida
Больница занимает 32-е место в этом списке по указанному рейтингу (4.3/5, 28 отзывов).
🇮🇳 Fortis Escorts Hospital Jaipur
Больница занимает 33-е место в этом списке по указанному рейтингу (4.3/5, 132 отзывов).
🇮🇳 Max Super Speciality Hospital, Saket
Больница занимает 34-е место в этом списке по указанному рейтингу (3.8/5, 49 отзывов).
🇮🇳 BLK-Max Super Speciality Hospital
Больница занимает 35-е место в этом списке по указанному рейтингу (3.8/5, 48 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Неврология» указано среди её специализаций и она находится в Дели (NCR), Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «brain tumor surgery» в Дели (NCR), Индия?
Выбор подходящей больницы для «brain tumor surgery» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Неврология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Brain Tumor Surgery»
Brain tumor surgery encompasses a spectrum of neurosurgical interventions—from craniotomy and endoscopic resection to stereotactic radiosurgery—designed to remove, debulk, or ablate benign and malignant intracranial neoplasms, with gross total resection achieved in 70–90% of eligible cases depending on tumor grade, location, and histology. Patients traveling through GAF Healthcare gain access to JCI- and NABH-accredited neurosurgical centers in India and JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi, where multidisciplinary tumor boards, intraoperative MRI (iMRI), fluorescence-guided surgery (5-ALA), and awake craniotomy protocols deliver outcomes benchmarked against leading Western institutions—at a fraction of the cost. India offers the most competitive pricing in Asia while the UAE provides ultra-premium facilities with seamless connectivity for patients from the Gulf, Africa, and Europe. Hospital Stay: 7–14 days (ICU: 1–3 days, ward: 6–11 days; varies by tumor grade and surgical approach) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (short-haul up to 4 hours may be cleared at 3–4 weeks post-op with neurosurgeon approval; long-haul intercontinental travel typically requires 6–8 weeks and a normal post-operative MRI) • Success Rate: 75–92% gross total or near-total resection rate for surgically accessible tumors (WHO Grade I–II); 5-year survival for glioblastoma with surgery + temozolomide + radiotherapy: 10–15%; meningioma resection cure rate (Simpson Grade I): >90%
Clinical Overview
A brain tumor is an abnormal proliferation of cells within the cranial vault—either primary (originating from glial, meningeal, or neural cells) or metastatic (seeded from lung, breast, colorectal, renal, or melanoma primaries). Primary brain tumors are classified by the WHO 2021 CNS classification system, which integrates histology with molecular markers such as IDH1/IDH2 mutation status, MGMT promoter methylation, 1p/19q co-deletion, TERT promoter mutation, and EGFR amplification. These markers are now mandatory for surgical planning and adjuvant therapy decisions. The tumor's mass effect—cerebral edema, midline shift, herniation, and hydrocephalus—produces the clinical syndrome of raised intracranial pressure (ICP), focal neurological deficits, seizures, and cognitive change. The physiological consequences of an untreated or inadequately managed brain tumor extend beyond the lesion itself. Peritumoral edema driven by vascular endothelial growth factor (VEGF) disrupts the blood-brain barrier, causing progressive neurological deterioration. Obstructive hydrocephalus from posterior fossa or intraventricular tumors can produce a neurosurgical emergency requiring urgent ventriculostomy or ventriculoperitoneal (VP) shunting. Corticosteroids (dexamethasone 4–16 mg/day) are used perioperatively to reduce edema, while antiepileptic drugs (levetiracetam is preferred) are administered prophylactically in supratentorial lesions. The modern standard of care for brain tumors is delivered by a multidisciplinary neuro-oncology team comprising neurosurgeons, neuroradiologists, neuropathologists, radiation oncologists, and medical oncologists. Surgery remains the cornerstone for tissue diagnosis, ICP relief, and cytoreduction. Maximum safe resection—guided by functional MRI (fMRI), diffusion tensor imaging (DTI) tractography, intraoperative neurophysiological monitoring (IONM), and 5-ALA fluorescence—is the primary surgical objective. Adjuvant therapy is tailored by molecular profile: temozolomide chemotherapy for IDH-mutant and MGMT-methylated gliomas, bevacizumab for recurrent glioblastoma, targeted BRAF inhibitors (dabrafenib + trametinib) for BRAF V600E-mutant tumors, and immunotherapy (pembrolizumab) for mismatch repair-deficient CNS tumors.
Who is a Candidate?
• WHO Performance Status (ECOG 0–2) indicating adequate functional reserve for general anesthesia and craniotomy • Radiologically confirmed intracranial mass on contrast-enhanced MRI Brain (1.5T or 3T with gadolinium) with evidence of mass effect, ring enhancement, or progressive growth • Surgical accessibility confirmed by neurovascular mapping: tumors located in non-eloquent cortex, or in eloquent areas where awake craniotomy can preserve function • Age typically 18–75 years; pediatric brain tumors (medulloblastoma, ependymoma, DIPG) assessed separately by pediatric neurosurgery board • Histological diagnosis required: tissue biopsy (stereotactic or open) is mandatory prior to adjuvant therapy; liquid biopsy (CSF ctDNA) emerging as adjunct • Required pre-operative diagnostics: Contrast-Enhanced MRI Brain and Spine (3T preferred), MR Spectroscopy, functional MRI (fMRI) for eloquent cortex mapping, Diffusion Tensor Imaging (DTI) for white matter tractography, PET-CT with FDG or FET-PET for metabolic activity grading and metastatic workup, CT Angiography or DSA for highly vascular tumors (meningioma, hemangioblastoma), Neuropsychological assessment, Complete blood count, coagulation profile (PT/INR/aPTT), comprehensive metabolic panel, and cardiac evaluation (ECG, ECHO) for patients over 50 or with cardiac history • Molecular tumor profiling: IDH1/IDH2, MGMT methylation, EGFR, 1p/19q, TERT promoter, and next-generation sequencing (NGS) panel recommended for all WHO Grade II–IV gliomas • CONTRAINDICATIONS: Karnofsky Performance Score (KPS) <50 indicating inability to tolerate surgery; deeply seated eloquent tumors with unacceptable neurological deficit risk (relative contraindication—stereotactic biopsy or radiosurgery considered); active systemic infection or sepsis; uncorrected coagulopathy; leptomeningeal carcinomatosis without dominant resectable lesion; patient refusal of blood products where required
Treatment Options & Approaches
SURGICAL APPROACHES: • Craniotomy with Microsurgical Resection: The gold standard for most supratentorial and posterior fossa tumors. A bone flap is elevated, the dura opened, and the tumor resected under high-magnification operative microscopy. Intraoperative MRI (iMRI, Siemens MAGNETOM) allows real-time assessment of resection completeness, enabling surgeons to re-operate within the same session if residual tumor is detected—increasing gross total resection (GTR) rates by 20–30%. • 5-Aminolevulinic Acid (5-ALA) Fluorescence-Guided Surgery: Patients ingest 5-ALA 3 hours pre-operatively; malignant glioma cells selectively accumulate protoporphyrin IX, which fluoresces pink-violet under a BLUE 400 surgical microscope. This technique significantly increases GTR rates for glioblastoma (65% vs. 36% in landmark Stummer et al. trial) and is standard of care at leading Indian and UAE neurosurgical centers. • Awake Craniotomy with Intraoperative Brain Mapping: For tumors in or adjacent to eloquent cortex (Broca's area, Wernicke's area, primary motor/sensory cortex), the patient is kept awake during resection. Real-time cortical and subcortical stimulation mapping (direct electrical stimulation, DES) identifies functional boundaries, maximizing resection while preserving language, motor, and cognitive function. Neuropsychologists, speech therapists, and specially trained anesthesiologists (asleep-awake-asleep technique) are integral to the team. • Endoscopic Brain Surgery: Fully endoscopic or endoscope-assisted approaches are used for intraventricular tumors (colloid cysts, ependymomas, subependymal giant cell astrocytomas), pituitary adenomas (transsphenoidal endoscopic resection via the nostril with no external incision), and posterior fossa tumors. Key-hole craniotomies (supraorbital, retrosigmoid) minimize brain retraction and reduce hospital stay. • Stereotactic Biopsy: For deep-seated or eloquent lesions not amenable to open resection, frame-based (Leksell) or frameless (Neuronavigation O-arm/iMRI-guided) stereotactic biopsy provides tissue diagnosis with sub-millimeter accuracy and <1% mortality risk. • Neuronavigation (BrainLab/Medtronic StealthStation): Pre-operative imaging (MRI + DTI + fMRI) is co-registered to the patient's anatomy intraoperatively, providing GPS-like surgical navigation that reduces the risk of inadvertent eloquent cortex or critical white matter tract injury. • Intraoperative Neurophysiological Monitoring (IONM): Continuous monitoring of motor evoked potentials (MEPs), somatosensory evoked potentials (SSEPs), and electrocorticography (ECoG) provides real-time feedback on cortical and subcortical function throughout resection, serving as an early warning system for neurological injury. RADIOSURGERY (NON-INVASIVE): • Stereotactic Radiosurgery (SRS): Gamma Knife (Elekta Leksell Gamma Knife Icon), CyberKnife (Accuray), or LINAC-based SRS delivers ablative radiation doses (12–24 Gy in 1–5 fractions) with sub-millimeter accuracy to residual tumor, recurrent lesions, or surgical contraindicated patients. Indicated for brain metastases ≤4 lesions, acoustic neuromas, meningiomas (Simpson Grade III–IV), recurrent AVM, and post-surgical residual glioma. • Laser Interstitial Thermal Therapy (LITT): A minimally invasive technique (NeuroBlate/Monteris system) where a laser probe is stereotactically placed into a deep-seated or radiation-recurrent tumor and thermal ablation destroys tumor cells under real-time MRI thermometry. Particularly useful for radiation necrosis, recurrent glioblastoma, and thalamic or basal ganglia tumors. ADJUVANT ONCOLOGICAL THERAPY (Post-Surgical): • Stupp Protocol (Glioblastoma, IDH-wildtype WHO Grade IV): Concurrent temozolomide 75 mg/m²/day during radiotherapy (60 Gy in 30 fractions), followed by 6 cycles of adjuvant temozolomide 150–200 mg/m² (Days 1–5 of 28-day cycle). MGMT promoter methylation is predictive of temozolomide benefit. • TTFields (Tumor Treating Fields, Optune device): Alternating electric fields delivered via transducer arrays applied to the scalp, FDA-approved for newly diagnosed and recurrent glioblastoma, extending median survival when added to standard chemoradiation. • Bevacizumab (anti-VEGF): For recurrent glioblastoma, often combined with lomustine or temozolomide. • Targeted Therapy: BRAF inhibitors (dabrafenib + trametinib) for BRAF V600E-mutant gliomas and pediatric low-grade gliomas; larotrectinib/entrectinib for NTRK fusion-positive CNS tumors; IDH inhibitors (ivosidenib, vorasidenib) for IDH-mutant low-grade gliomas—vorasidenib FDA-approved 2024. • Immunotherapy: Pembrolizumab and nivolumab for MSI-high or TMB-high CNS tumors; ongoing trials for glioblastoma.
Восстановление
PRE-OPERATIVE PHASE (Days -14 to 0): Step 1 — Remote Case Review (Before Travel): Patient submits MRI Brain (DICOM files), biopsy reports (if available), molecular pathology, and clinical history to GAF Healthcare's neurosurgical panel. A senior neurosurgeon reviews the case within 48–72 hours and issues a written surgical opinion including recommended approach, estimated duration, expected outcomes, and a provisional cost estimate. Video consultation is arranged if required. Step 2 — Travel and Pre-Admission (Days -3 to -1): Patient and one attendant arrive in India or the UAE. GAF Healthcare coordinator manages airport pickup, hotel accommodation near the hospital, and hospital registration. Pre-operative workup is completed: contrast MRI Brain ± Spine, fMRI, DTI, PET-CT, neuropsychological baseline, blood work, cardiac clearance, and anesthesiology pre-assessment. Dexamethasone is initiated if significant edema is present. Levetiracetam is started for seizure prophylaxis in supratentorial tumors. Step 3 — Pre-Operative Planning Conference: The multidisciplinary tumor board (neurosurgeon, neuroradiologist, neuro-oncologist, radiation oncologist, neuropathologist) reviews all imaging and plans the surgical strategy: craniotomy vs. endoscopy vs. biopsy; awake vs. asleep; 5-ALA fluorescence protocol; IONM modalities required. Surgical plan is uploaded to the BrainLab/Stealthstation navigation system. THE PROCEDURE (Day 0, Duration: 4–12 hours depending on tumor complexity): Step 4 — Anesthesia and Positioning: General anesthesia (or asleep-awake-asleep for awake craniotomy). Patient positioned in a Mayfield pin-head fixation device. Neuronavigation system registered to patient anatomy using intraoperative surface scanning or fiducial markers. Step 5 — Craniotomy: Scalp incision, burr holes placed, and bone flap elevated. Dura opened in curvilinear fashion. Cortical mapping performed (direct electrical stimulation or awake mapping). Surgical approach corridor planned to minimize retraction of normal brain. Step 6 — Tumor Resection: Microsurgical resection under operative microscope with 5-ALA fluorescence guidance. IONM team monitors MEPs and SSEPs continuously. Intraoperative ultrasound or iMRI confirms degree of resection. Hemostasis achieved with bipolar cautery, hemostatic agents (Surgicel, FloSeal). Dura closed watertight (synthetic dural substitute if needed). Bone flap replaced and fixed with titanium plates. Scalp closed in layers. Step 7 — Immediate Post-Operative Care (ICU, Days 1–3): Patient transferred to Neuro-ICU for continuous neurological monitoring (GCS, pupillary responses, ICP monitoring if indicated). CT Brain performed within 6 hours post-operatively to exclude hemorrhage or edema. Dexamethasone continued and tapered. Levetiracetam continued. Early post-operative MRI (24–72 hours) to assess resection extent. POST-OPERATIVE RECOVERY (Days 3–14, Ward Phase): Step 8 — Neurological Rehabilitation Initiation: Physical therapy, occupational therapy, and speech therapy begin as early as Day 1–2. Swallowing assessment for posterior fossa surgeries. DVT prophylaxis (LMWH, compression stockings) initiated 24–48 hours post-op. Step 9 — Wound Care and Suture Removal: Surgical staples or sutures removed at Day 10–14. Wound assessed for CSF leak, infection, or dehiscence. Step 10 — Adjuvant Therapy Planning: Molecular pathology results (IDH, MGMT, 1p/19q) available within 7–14 days. Multidisciplinary team meets to finalize adjuvant chemoradiation schedule. Radiation planning CT and simulation performed if radiotherapy is to be delivered locally in India or UAE before departure. Step 11 — Discharge and Post-Operative MRI: Patient discharged with detailed clinical summary, molecular pathology report, surgical operative note, and adjuvant therapy recommendation letter. First post-operative MRI (contrast-enhanced) performed at 2–4 weeks post-op as baseline for surveillance. FIT-TO-FLY AND LONG-TERM MILESTONES: • 3–4 weeks post-op: Cleared for short-haul flights (<4 hours) if wound healed, neurologically stable, no VTE, and neurosurgeon approval obtained. • 6–8 weeks post-op: Cleared for long-haul intercontinental travel; adjuvant temozolomide cycles can continue in home country with the treatment protocol provided by GAF Healthcare's oncology team. • 3 months: Follow-up MRI (pseudo-progression vs. true progression assessment using MR Perfusion and Spectroscopy). • 6 months and annually: Surveillance MRI; neuropsychological follow-up; quality of life assessment.
Возможные риски
Brain tumor surgery carries procedure-specific risks that patients must understand before providing informed consent. Neurological deficits—including new or worsened motor weakness, speech disturbance (aphasia or dysarthria), visual field defects, or cognitive change—occur in 10–25% of cases involving tumors in or adjacent to eloquent cortex; the majority are transient, resolving within 6–12 weeks with rehabilitation, but a minority (5–8%) may be permanent. Cerebral edema peaking at 48–72 hours post-operatively can cause clinical deterioration requiring aggressive corticosteroid therapy or, rarely, surgical decompression. Intracranial hemorrhage at the resection cavity occurs in 2–5% of cases and may require urgent re-exploration. Infection—surgical site infection, meningitis, or cerebral abscess—occurs in 1–3% of cases; risk is higher with prolonged surgery, CSF leak, or external ventricular drainage. Cerebrospinal fluid (CSF) leak manifesting as rhinorrhea, otorrhea, or wound pseudomeningocele occurs in 3–7% of posterior fossa and skull base surgeries; most resolve with lumbar drainage but may require surgical repair. Venous thromboembolism (DVT and pulmonary embolism) is a significant risk in neurosurgical patients due to immobility and pro-coagulant tumor microenvironment; routine prophylaxis with low-molecular-weight heparin and mechanical compression devices is standard. Seizures, new-onset or exacerbated, affect 10–30% of supratentorial tumor patients perioperatively; antiepileptic therapy is continued for a minimum of 3–12 months. For posterior fossa tumors, cranial nerve palsies (particularly CN V, VII, VIII, IX, X) and cerebellar mutism (in pediatric patients) are recognized complications. General anesthesia risks include pulmonary complications, deep vein thrombosis, and cardiovascular events, which are mitigated by thorough pre-operative cardiac and pulmonary assessment. Patients should be counseled that gross total resection does not equal cure for high-grade gliomas; recurrence remains the rule for glioblastoma despite optimal surgery and chemoradiation, and ongoing surveillance MRI is non-negotiable.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical coordination for brain tumor surgery patients traveling to India or the UAE, ensuring that patients and their families can focus entirely on treatment and recovery. INDIA — VISA AND ENTRY: GAF Healthcare's dedicated visa team assists patients in applying for the Indian e-Medical Visa (e-MV), which is specifically designed for patients traveling for medical treatment and covers one accompanying attendant on an e-Medical Attendant Visa. The e-Medical Visa permits a stay of up to 60 days, extendable within India, and allows multiple entries. Required documents—hospital invitation letter, GAF Healthcare's registered medical institution letter, passport copies, and travel itinerary—are prepared and submitted by our coordinators. Visa approval is typically granted within 3–5 working days. UAE (DUBAI / ABU DHABI) — VISA AND ENTRY: Passport holders from 49+ countries, including EU, UK, US, Canada, Australia, and GCC nationals, enjoy visa-free access to the UAE or receive a visa on arrival. For nationalities requiring prior visa, GAF Healthcare facilitates the UAE Medical Visa application process through the General Directorate of Residency and Foreigners Affairs (GDRFA), with the hospital's formal treatment confirmation serving as the supporting document. Visa-on-arrival extensions up to 30 days are available for medical cases and are coordinated by our UAE case managers. AIRPORT TRANSFERS AND LOCAL TRANSPORT: Private ambulance or wheelchair-accessible vehicle transfers are arranged for all arrival and departure journeys. For patients with active neurological deficits—hemiparesis, aphasia, or altered consciousness—medically supervised transfers with a paramedic attendant can be arranged between airport and hospital. DEDICATED PATIENT COORDINATORS AND TRANSLATORS: Each patient is assigned a dedicated GAF Healthcare case manager who remains the single point of contact throughout the treatment journey. Professional medical interpreters are available in Arabic, Russian, French, Swahili, Bengali, and other languages for patient consultations, consent discussions, and discharge briefings. Interpretation is provided in person for surgical consent and telephonically for daily clinical updates. ACCOMMODATION FOR ATTENDANTS: GAF Healthcare partners with hospitals offering in-room attendant cots or attached attendant rooms at no additional charge during the ICU and acute ward phase. For the post-discharge recovery period (Weeks 2–8), we arrange serviced apartments or partner hotels within 1–2 km of the treating hospital, offering medical-grade hygiene standards, dietary meal options (including culturally appropriate and halal menus), and 24-hour concierge support. Monthly rental packages are negotiated at preferential rates for GAF Healthcare patients. TELEMEDICINE FOLLOW-UP AFTER RETURN HOME: Post-departure follow-up consultations with the treating neurosurgeon and neuro-oncologist are conducted via secure video link at 4 weeks, 3 months, and 6 months. MRI and laboratory reports from the patient's home country are reviewed remotely, and adjuvant therapy guidance is communicated to the patient's local oncologist in a structured clinical handover letter.
Частые вопросы о процедуре «Brain Tumor Surgery»
What is the cost of brain tumor surgery in India compared to the UAE?
How long do I need to stay in the country before I am fit to fly home after brain tumor surgery?
What is the success rate of brain tumor surgery?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «brain tumor surgery» в Дели (NCR), Индия
Найдите лучшие больницы для «brain tumor surgery» в Дели (NCR), Индия
На этой странице представлено 35 больниц в Дели (NCR), Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Brain Tumor Surgery» в Дели (NCR), Индия
Сколько больниц направления «Неврология» представлено в Дели (NCR), Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Дели (NCR), Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Brain Tumor Surgery» в Дели (NCR), Индия.
Свяжитесь с нами, если заметите неточность на этой странице.